Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases

Breast cancer is the second most common cause of brain metastases (BM). Despite increasing incidence of BM in older women, there are limited data on the optimal management of BM in this age group. In this study, we assessed the survival outcomes and treatment patterns of older breast cancer patients...

Full description

Saved in:

Bibliographic Details
Published in:	Cancers 2023-12, Vol.16 (1), p.137
Main Authors:	Upadhyay, Rituraj, Klamer, Brett G, Perlow, Haley K, White, Julia R, Bazan, Jose G, Jhawar, Sachin R, Blakaj, Dukagjin M, Grecula, John C, Arnett, Andrea, Mestres-Villanueva, Mariella A, Healy, Erin H, Thomas, Evan M, Chakravarti, Arnab, Raval, Raju R, Lustberg, Maryam, Williams, Nicole O, Palmer, Joshua D, Beyer, Sasha J
Format:	Article
Language:	eng
Subjects:	Adverse events Biopsy Breast cancer Cancer Cancer therapies Care and treatment Cognition Comparative analysis Decision making Development and progression Effectiveness ErbB-2 protein geriatric cancer Medical prognosis Meninges Metastases Metastasis oligometastases Oncology, Experimental Patients Planning Quality of life Radiation Radiation therapy Radiosurgery Regression analysis stereotactic radiosurgery Surgery Survival Survival analysis Tumors Womens health
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Breast cancer is the second most common cause of brain metastases (BM). Despite increasing incidence of BM in older women, there are limited data on the optimal management of BM in this age group. In this study, we assessed the survival outcomes and treatment patterns of older breast cancer patients ≥65 years old with BM compared to younger patients at our institution. An IRB-approved single-institutional retrospective review of biopsy-proven breast cancer patients with BM treated with 1- to 5-fraction stereotactic radiation therapy (SRS) from 2015 to 2020 was performed. Primary endpoint was intracranial progression-free survival (PFS) defined as the time interval between the end of SRS to the date of the first CNS progression. Secondary endpoints were overall survival (OS) from the end of SRS and radiation treatment patterns. Kaplan-Meier estimates and Cox proportional hazard regression method were used for survival analyses. A total of 112 metastatic breast cancer patients with BMs were included of which 24 were ≥65 years old and 88 were
ISSN:	2072-6694 2072-6694